Literature DB >> 9665604

Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen.

W Hauber1, J Nagel, R Sauer, C E Müller.   

Abstract

Motor effects mediated through adenosine A2A receptors within the caudate-putamen were investigated in rats using bilateral microinfusions of MSX-3 (9 microg in 1 microl per side), a water-soluble phosphate prodrug of the selective A2A receptor antagonist MSX-2. Blockade of striatal A2A receptors produced a significant motor stimulation measured by an enhanced sniffing activity. Furthermore, catalepsy induced by systemic dopamine D1 (0.75 mg/kg SCH23390, i.p.) or dopamine D2 receptor blockade (1.5 mg/kg raclopride, i.p.) was potently reversed. These findings suggest that A2A receptors within the caudate-putamen are tonically activated by endogenous adenosine and that a striatal A2A receptor blockade produces motor stimulant effects, in particular in animals with dopamine hypofunction. The present results support the view that A2A receptor antagonists may be potentially useful therapeutics for the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665604     DOI: 10.1097/00001756-199806010-00024

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

1.  Functional uncoupling of adenosine A(2A) receptors and reduced responseto caffeine in mice lacking dopamine D2 receptors.

Authors:  N R Zahniser; J K Simosky; R D Mayfield; C A Negri; T Hanania; G A Larson; M A Kelly; D K Grandy; M Rubinstein; M J Low; B B Fredholm
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Adenosine A2A receptors in the nucleus accumbens bi-directionally alter cocaine seeking in rats.

Authors:  Casey E O'Neill; McKenzie L LeTendre; Ryan K Bachtell
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

Review 3.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

4.  Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.

Authors:  Keita Ishiwari; Lisa J Madson; Andrew M Farrar; Susana M Mingote; John P Valenta; Michael D DiGianvittorio; Lauren E Frank; Merce Correa; Jörg Hockemeyer; Christa Müller; John D Salamone
Journal:  Behav Brain Res       Date:  2006-12-21       Impact factor: 3.332

Review 5.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

6.  Stimulation of adenosine receptors in the nucleus accumbens reverses the expression of cocaine sensitization and cross-sensitization to dopamine D2 receptors in rats.

Authors:  Benjamin D Hobson; Kathryn E Merritt; Ryan K Bachtell
Journal:  Neuropharmacology       Date:  2012-06-28       Impact factor: 5.250

7.  Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists.

Authors:  Talia N Lerner; Eric A Horne; Nephi Stella; Anatol C Kreitzer
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

Review 8.  Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.

Authors:  Robert A Hauser; Michael A Schwarzschild
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

9.  Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.

Authors:  Ming Yang; Daniel Soohoo; Sandriyana Soelaiman; Rao Kalla; Jeff Zablocki; Nancy Chu; Kwan Leung; Lina Yao; Ivan Diamond; Luiz Belardinelli; John C Shryock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-20       Impact factor: 3.000

10.  Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease.

Authors:  M Morelli; J Wardas
Journal:  Neurotox Res       Date:  2001-11       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.